Your browser doesn't support javascript.
loading
The third nationwide surveillance of antimicrobial susceptibility against Neisseria gonorrhoeae from male urethritis in Japan, 2016-2017.
Yasuda, Mitsuru; Takahashi, Satoshi; Miyazaki, Jun; Wada, Koichiro; Kobayashi, Kanao; Matsumoto, Masahiro; Hayami, Hiroshi; Yamamoto, Shingo; Kiyota, Hiroshi; Sato, Junko; Matsumoto, Tetsuya; Yotsuyanagi, Hiroshi; Hanaki, Hideaki; Masumori, Naoya; Hiyama, Yoshiki; Nishiyama, Hiroyuki; Kimura, Takahiro; Yamada, Hiroki; Matsumoto, Kazumasa; Ishikawa, Kiyohito; Togo, Yoshikazu; Tanaka, Kazushi; Sadahira, Takuya; Inokuchi, Junichi; Hamasuna, Ryoichi; Ito, Kenji; Hirayama, Hideo; Hayashi, Kenji; Kurimura, Yuichiro; Kadena, Hitoshi; Ito, Shin; Shiono, Yutaka; Maruyama, Takahiro; Ito, Masayasu; Hatano, Koichi; Chokyu, Hirofumi; Ihara, Hideari; Uno, Satoshi; Monden, Koichi; Yokoyama, Teruhiko; Kano, Motonori; Kaji, Shinichi; Kawahara, Motoshi; Sumii, Toru; Tojo, Takanori; Hosobe, Takahide; Naito, Kazuhiko; Kawai, Shuichi; Nishimura, Hirofumi; Izumitani, Masanobu.
Afiliación
  • Yasuda M; The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Infection Control and Laboratory Medicine, Sapporo Med
  • Takahashi S; The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Infection Control and Laboratory Medicine, Sapporo Med
  • Miyazaki J; The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, International University of Health and Welfar
  • Wada K; The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Faculty of Medicine, Shimane University, Izum
  • Kobayashi K; The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Chugoku Rosai Hospital, Hiroshima, Japan.
  • Matsumoto M; The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, University of Occupational and Environmental
  • Hayami H; The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Blood Purification Center, Kagoshima University Hospital, Kagoshima,
  • Yamamoto S; The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Hyogo College of Medicine, Nishinomiya, Japan
  • Kiyota H; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan; Department of Urology, School of Medicine, The Jikei University Katsushika Medical Center, Tokyo, Japan.
  • Sato J; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
  • Matsumoto T; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
  • Yotsuyanagi H; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
  • Hanaki H; Research Center for Anti-infectious Drugs, Kitasato Institute for Life Science, Kitasato University, Tokyo, Japan.
  • Masumori N; Department of Urology, School of Medicine, Sapporo Medical University, Sapporo, Japan.
  • Hiyama Y; Department of Urology, School of Medicine, Sapporo Medical University, Sapporo, Japan.
  • Nishiyama H; Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Kimura T; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Yamada H; Department of Urology, School of Medicine, The Jikei University Katsushika Medical Center, Tokyo, Japan.
  • Matsumoto K; Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan.
  • Ishikawa K; Department of Urology, School of Medicine, Fujita Health University, Toyoake, Japan.
  • Togo Y; Department of Urology, Hyogo College of Medicine, Nishinomiya, Japan.
  • Tanaka K; Division of Urology, Kobe University, Kobe, Japan.
  • Sadahira T; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Inokuchi J; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Hamasuna R; Department of Urology, University of Occupational and Environmental Health, Japan, Fukuoka, Japan.
  • Ito K; Ito Urology Clinic, Kitakyushu, Japan.
  • Hirayama H; Hirayama Urology Clinic, Kumamoto, Japan.
  • Hayashi K; Department of Urology, Tomakomai Urological Clinic, Hokkaido, Japan.
  • Kurimura Y; Department of Urology, Tomakomai Urological Clinic, Hokkaido, Japan.
  • Kadena H; Kadena Urology Clinic, Hiroshima, Japan.
  • Ito S; IClinic, Sendai, Japan.
  • Shiono Y; Aioi23Clinic, Yokohama, Japan.
  • Maruyama T; Maruyama Urology Clinic, Nagoya, Japan.
  • Ito M; Gifu Urological Clinic, Gifu, Japan.
  • Hatano K; Hatano Urology and Dermatology Clinic, Gifu, Japan.
  • Chokyu H; Chokyu Tenma Clinic, Himeji, Japan.
  • Ihara H; Ihara Clinic, Nishinomiya, Japan.
  • Uno S; Hirajima Clinic, Okayama, Japan.
  • Monden K; Araki Urological Clinic, Kurashiki, Japan.
  • Yokoyama T; Yokoyama Urological Clinic, Okayama, Japan.
  • Kano M; Department of Urology, Kano Hospital, Kasuya-gun, Japan.
  • Kaji S; Kaji Clinic, Fukuoka, Japan.
  • Kawahara M; Kawahara Urology Clinic, Kagoshima, Japan.
  • Sumii T; Sumii Clinic, Hiroshima, Japan.
  • Tojo T; Tomei Atsugi Hospital, Atsugi, Japan.
  • Hosobe T; Hosobe Clinic, Tokyo, Japan.
  • Naito K; Naito Urology and Nephrology Clinic, Nagoya, Japan.
  • Kawai S; Kawai Urology Clinic, Kitakyushu, Japan.
  • Nishimura H; Nishimura Urology Clinic, Kitakyushu, Japan.
  • Izumitani M; Izumitani Fureai Clinic, Nagoya, Japan.
J Infect Chemother ; 29(11): 1011-1016, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37553046
ABSTRACT
Neisseria gonorrhoeae is one of the important pathogens of sexually transmitted infections. N. gonorrhoeae is rapidly becoming antimicrobial resistant, and there are few drugs that are effective in the initial treatment of gonorrhea. To understand the trends of antimicrobial susceptibility of N. gonorrhoeae, the Surveillance Committee of the Japanese Society of Infectious Diseases, the Japanese Society for Chemotherapy, and the Japanese Society of Clinical Microbiology conducted the third nationwide antimicrobial susceptibility surveillance of N. gonorrhoeae isolated from male urethritis. The specimens were collected from male patients with urethritis at 30 facilities from May 2016 to July 2017. From the 159 specimens collected, 87 N. gonorrhoeae strains were isolated, and 85 were tested for susceptibility to 21 antimicrobial agents. All strains were non-susceptible to penicillin G. Seven strains (8.2%) were ß-lactamase-producing strains. The rates of susceptibility to cefixime and cefpodoxime were 96.5% and 52.9%, respectively. Three strains were non-susceptible with a minimum inhibitory concentration (MIC) of 0.5 mg/L for cefixime. None of the strains were resistant to ceftriaxone or spectinomycin. The susceptibility rate for ciprofloxacin was 23.5% (20 strains), and no strains showed intermediate susceptibility. The susceptibility rate against azithromycin was 81.2%, with one strain isolated with a MIC of 8 mg/L against azithromycin. The results of this surveillance indicate that ceftriaxone and spectinomycin, which are currently recommended for gonococcal infections in Japan, appear to be effective. It will be necessary to further expand the scale of the next surveillance to understand the current status of drug-resistant N. gonorrhoeae in Japan.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uretritis / Gonorrea / Antiinfecciosos Tipo de estudio: Screening_studies Límite: Humans / Male País/Región como asunto: Asia Idioma: En Revista: J Infect Chemother Asunto de la revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uretritis / Gonorrea / Antiinfecciosos Tipo de estudio: Screening_studies Límite: Humans / Male País/Región como asunto: Asia Idioma: En Revista: J Infect Chemother Asunto de la revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article